These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 35282462)
1. Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling. Galuppini F; Censi S; Merante Boschin I; Fassan M; Sbaraglia M; Valeri N; Hahne JC; Bertazza L; Munari G; Galasso M; Cascione L; Barollo S; Rugge M; Vianello F; Dei Tos AP; Mian C; Pennelli G Front Endocrinol (Lausanne); 2022; 13():834075. PubMed ID: 35282462 [TBL] [Abstract][Full Text] [Related]
2. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas. Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448 [TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505 [TBL] [Abstract][Full Text] [Related]
4. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features. Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation. Celakovsky P; Kovarikova H; Chrobok V; Mejzlik J; Laco J; Vosmikova H; Chmelarova M; Ryska A In Vivo; 2021; 35(1):319-323. PubMed ID: 33402480 [TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma. Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400 [TBL] [Abstract][Full Text] [Related]
8. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953 [TBL] [Abstract][Full Text] [Related]
9. BRAF mutation, selected miRNAs and genes expression in primary papillary thyroid carcinomas and local lymph node metastases. Kalfert D; Ludvikova M; Pesta M; Hakala T; Dostalova L; Grundmannova H; Windrichova J; Houfkova K; Knizkova T; Ludvik J; Polivka J; Kholova I Pathol Res Pract; 2024 Jun; 258():155319. PubMed ID: 38696857 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871 [TBL] [Abstract][Full Text] [Related]
11. MicroRNA Profiling in Papillary Thyroid Cancer. Armos R; Bojtor B; Papp M; Illyes I; Lengyel B; Kiss A; Szili B; Tobias B; Balla B; Piko H; Illes A; Putz Z; Kiss A; Toth E; Takacs I; Kosa JP; Lakatos P Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273308 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of miR-7-5p and miR-548ar-5p predicts malignancy in indeterminate thyroid nodules negative for BRAF and RAS mutations. Macerola E; Poma AM; Proietti A; Rago T; Romani R; Vignali P; Ugolini C; Torregrossa L; Basolo A; Santini F; Basolo F Endocrine; 2022 Jun; 76(3):677-686. PubMed ID: 35347579 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting. Napoli F; Rapa I; Mortara U; Massa F; Izzo S; Rigutto A; Zambelli V; Bellevicine C; Troncone G; Papotti M; Volante M Cancer Cytopathol; 2022 Sep; 130(9):695-704. PubMed ID: 35500065 [TBL] [Abstract][Full Text] [Related]
14. BRAF Gao Y; Xiang D; Li W; Zheng X; Wang L; Li Z; Chen T Front Endocrinol (Lausanne); 2022; 13():843334. PubMed ID: 35651980 [No Abstract] [Full Text] [Related]
15. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. Chou CK; Chen RF; Chou FF; Chang HW; Chen YJ; Lee YF; Yang KD; Cheng JT; Huang CC; Liu RT Thyroid; 2010 May; 20(5):489-94. PubMed ID: 20406109 [TBL] [Abstract][Full Text] [Related]
16. [Clinicopathological features and molecular characteristics of tall cell and hobnail variants of papillary thyroid carcinoma]. Zhang M; Duan HL; Wang LM; Gao W; Yao YY; Teng LH Zhonghua Bing Li Xue Za Zhi; 2021 Nov; 50(11):1234-1239. PubMed ID: 34719160 [No Abstract] [Full Text] [Related]
17. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Geraldo MV; Nakaya HI; Kimura ET Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816 [TBL] [Abstract][Full Text] [Related]
19. In-depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma. Swierniak M; Wojcicka A; Czetwertynska M; Stachlewska E; Maciag M; Wiechno W; Gornicka B; Bogdanska M; Koperski L; de la Chapelle A; Jazdzewski K J Clin Endocrinol Metab; 2013 Aug; 98(8):E1401-9. PubMed ID: 23783103 [TBL] [Abstract][Full Text] [Related]
20. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]